After successful pilot, Meaningful Adherence™ platform will aid 1.6 million health plan members in medication adherence
PORTLAND, Ore. and CAMBRIDGE, Mass. – August 19, 2014 – OmedaRx, a Cambia Health Solutions company, and GNS Healthcare, a leading provider of big data analytics solutions in health care, today announced the deployment of the GNS Meaningful Adherence™ platform to 1.6 million members within the Cambia Health Solutions family of health plan companies in Idaho, Utah, Washington and Oregon. The companies are …
Large-scale Patient Data Analytics Can Help Create Personalized, Early Intervention for Patients
CAMBRIDGE, Mass. and HARTFORD, Conn. – June 27, 2014 – Research published today in The American Journal of Managed Care demonstrates that analysis of patient records using state-of-the-art data analytics can predict future risk of metabolic syndrome. More than a third of the U.S. population has metabolic syndrome, a condition that can lead to chronic heart disease, stroke and diabetes. These conditions combine to account for almost 20 …
Dr. James Robins, Dr. Peter Neumann and Dr. Zak Kohane to help guide the company’s big data modeling efforts to improve patient outcomes and cost-effectiveness.
Cambridge, Mass. – May 20, 2014 – GNS Healthcare announced today the addition of three premier experts in their respective fields to the company’s Scientific Advisory Board (SAB). These included Dr. James Robins, the Mitchell L. and Robin LaFoley Dong Professor of Epidemiology at the Harvard School of Public Health; Dr. Peter Neumann, Director of …
Leading healthcare big data analytics firm strengthens leadership team with the addition of industry veteran Mark Pottle.
Cambridge, Mass, April 15, 2014. GNS Healthcare is pleased to announce that Mark Pottle has joined the company’s executive team as Chief Financial Officer. Mark has extensive experience in finance, M&A, business development and strategic operational leadership in both fast growing healthcare technology firms and a Fortune 50 diversified healthcare company.
Prior to joining GNS Healthcare, Mark was the CFO at N-of-One, a …
Strategic investors include Cambia Health Solutions, Mitsui USA and Heritage Provider Network
January 28, 2014 – CAMBRIDGE, Mass. – GNS Healthcare, a leading provider of big data analytics products and services in healthcare, today announced the completion of a $10M Series B financing. Cambia Health Solutions, a Series A investor, was joined in the round by two additional strategic investors: California’s Heritage Provider Network, and Mitsui & Co. (U.S.A.), Inc. (“Mitsui USA”). This round of financing will be used …
Patent covers automated causal modeling and simulation technologies
CAMBRIDGE, Mass. – Nov 26, 2013 – GNS Healthcare today announced that U.S. Patent 8,571,803, entitled “Systems and Methods for Modeling and Analyzing Networks,” has been issued, relating to significant innovations in automated causal data analytics. The patent covers key methods underlying REFS™, a computational platform that automatically builds predictive and explanatory models from big data.
“Healthcare companies can no longer afford to pursue a manual approach to data analytics”, said GNS …
Partners to Build and Commercialize Predictive Computer Models of Preterm Birth from Next Generation Sequencing and Electronic Medical Record Data
FALLS CHURCH, VA and CAMBRIDGE, Mass. – August 8, 2013 – The Inova Translational Medicine Institute (ITMI) at Inova Fairfax Hospital and GNS Healthcare today announced a partnership to develop and commercialize computer models capable of predicting risk of preterm live birth, built using next generation sequencing and electronic medical record data. GNS and ITMI will license the models and …
Meaningful Adherence™ Platform Could Help Reduce Adverse Events, Improve Outcomes and Lower Healthcare Costs
PORTLAND, Ore. and CAMBRIDGE, Mass. – June 27, 2013 – Cambia Health Solutions and GNS Healthcare today announced they are collaborating to build a platform for harnessing data-driven predictive models focused on medication adherence. The partnership will focus on predicting Meaningful Adherence™ – identifying where improving medication adherence can have the most meaningful impact on clinical and cost outcomes.
The Cambia family of companies includes leading …
Howard Weiner, Maria Pia Sormani, and Philip De Jager to guide company’s Big Data modeling efforts to improve patient outcomes
CAMBRIDGE, Mass. – June 3, 2013 – GNS Healthcare today announced that Dr. Howard Weiner, Dr. Maria Pia Sormani, and Dr. Philip De Jager have joined their newly formed Multiple Sclerosis Scientific Advisory Board. The members of the advisory board will lend their expertise to compliment GNS’s data-driven modeling technology as the company builds computational models of the disease.
GNS Healthcare, Inc. announced today that Harvard Medical School has licensed its REFS™ (Reverse Engineering and Forward Simulation) Big Data analytics platform. Under the five-year license, Harvard researchers will use REFS™ to characterize and understand signaling and transcriptional events in biological systems. Financial terms of the agreement were not disclosed.
“Reverse engineering is a key challenge for systems biology,” said Marc Kirschner, Professor and Chair of the Department of Systems Biology at Harvard Medical School. “Achieving a synergy between the design of experiments and reverse engineering methods will be defining for how we understand biological mechanism in the next century.”